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SUMMARY
A 34-year-old male presented to the endocrinology 
clinic with the complaint of the absence of facial, 
axillary and pubic hairs. Further history revealed absent 
ejaculations and decreased early morning erections. The 
patient had no history of headaches, visual problems or 
anosmia. On physical examination, there were sparse 
facial, axillary and pubic hairs, bilateral gynaecomastia, 
stretch penile length of 5 cm and bilateral testicular 
volume of 10 mL. Laboratory investigations showed 
low luteinising hormone, follicular stimulating hormone 
and testosterone with normal prolactin and thyroid 
profile. MRI of the pituitary gland showed no evidence of 
pituitary microadenoma or macroadenoma. The patient 
was started on testosterone injections. After 9 months 
of testosterone replacement, the patient’s testicular 
size increased to 20 mL bilaterally and his penile length 
increased to the mean adult size for his age with normal 
testosterone and luteinising hormone. He was, thus, 
advised to discontinue testosterone therapy.
BAckgRoUnd
Hypogonadotropic hypogonadism (HH) is a rela-
tively uncommon disorder with prevalence ranging 
from 1 in 10 000 to 1 in 86 000 individuals and 
a male to female ratio of 1:5.1 2 Idiopathic HH is 
diagnosed in the presence of low testosterone and 
follicular stimulating hormone/luteinising hormone 
without any structural or functional abnormalities 
in the hypothalamic–pituitary–gonadal (HPG) axis. 
It is primarily due to a flaw in the secretion or action 
of gonadotropin-releasing hormone (GnRH) and is 
diagnosed when there is a failure of sexual matura-
tion by 18 years of age.2
Typically, puberty is caused by the maturation 
of the HPG axis during which the pulsatile release 
of GnRH  by the hypothalamus causes secretion 
of luteinising hormone and follicular stimulating 
hormone by the pituitary gland. In males, this 
causes the production of testosterone and the matu-
ration of sperm.3 This results in the development 
of secondary sexual characteristics and attainment 
of fertility. Generally, puberty in boys starts around 
11 years of age and is complete by the age of 16–17 
years. Delayed puberty for boys is defined as the 
absence of testicular enlargement by an age 2–2.5 
SD above the mean for a given population (usually 
14 years of age).4 5
Both congenital and acquired forms of HH are 
present with the latter caused by chemotherapy, radi-
ation, damage to the pituitary gland/hypothalamus, 
malnutrition and hyperprolactinaemia among other 
reasons. Treatment of this condition is paramount 
because it leads to a significantly decreased quality 
of life and problems such as reduced muscle mass, 
energy, libido, facial and pubic hair, small genitalia, 
failure of voice to deepen, infertility, etc. Further-
more, patients might also develop low self-esteem, 
depression and osteoporosis later in life because of 
low testosterone levels in the body.6
cASe pReSentAtion
A 34-year-old male with no known co-mor-
bids presented to the endocrine clinic with the 
complaints of scarce facial, axillary and pubic 
hairs. The prompting factor for the patient to seek 
medical advice was that he wanted to get married 
soon. Further history revealed absent ejaculations 
and decreased early morning erections. There was 
no current or prior history of headache, visual prob-
lems, decreased sense of smell, trauma or radiation 
exposure. The patient was not using any medication 
or hormone therapy and had a sedentary lifestyle. 
Past medical, surgical and family history was unre-
markable.
On examination, the patient had a blood pressure 
of 116/70 mm Hg, pulse of 92 beats per minute, 
height of 172.5 cm and a weight of 68 kg. There 
were no facial hairs, sparse axillary and pubic hairs, 
bilateral gynaecomastia, stretch penile length of 5 
cm and bilateral testicular volume of 10 mL. The 
rest of the physical examination was unremark-
able. A diagnosis of hypogonadism was made and 
he was advised to have serum luteinising hormone, 
follicular stimulating hormone, testosterone (AM), 
prolactin, thyroid -stimulating hormone and free 
thyroxine tested.
inveStigAtionS
The laboratory reports of the patient showed 
luteinising hormone 2.60 mlU/mL (normal limit 
in males: 1.2–7.8), follicular stimulating hormone 
1.50 mlU/mL (normal limit in males: 1.5–15.4), 
ante meridiem (AM) testosterone 55.99 ng/dL 
(normal limit in males: 249–836), prolactin 5.2 ng/
mL (normal limit in males 2–18 ng/mL), thyroid 
stimulating hormone 1.03 ulU/mL (normal limit: 
0.4–4.2) and free thyroxine 1.13 ng/dL (normal 
limit: 0.89–1.76).
After biochemical confirmation of HH, he was 
advised MRI of the pituitary gland which showed 
a normal pituitary fossa with no evidence of pitu-
itary microadenoma or macroadenoma (figure 1). 
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The patient was subsequently started on testosterone injections. 




The patient was started on testosterone injection 250 mg once 
every 4 weeks which was later decreased to 250 mg once every 
6 weeks. At that time, the plan was to start the patient on pulsatile 
GnRH therapy once he got married in order to restore fertility.
oUtcoMe And follow-Up
At 3 months on follow-up, the morning testosterone peak level 
of the patient reached 643.3 ng/dL with trough level of 163.3 ng/
dL. After 9 months of testosterone replacement, the patient’s 
testicular size increased to 20  mL bilaterally and his penis length 
increased to the mean adult size for his age. He became well 
virilised. Considering the sexual maturation on clinical examina-
tion, patient was advised to hold testosterone replacement and 
his testosterone and luteinising hormone levels were rechecked 
after 2 months to see whether the hypothalamic–gonadal axis 
had recovered. His testosterone levels off replacement were 
433.8 ng/dL with a luteinising hormone level of 3.30 mlU/mL 
(1.2–7.8). The patient was, therefore, advised to stop testos-
terone. Table 2 shows the follow-up laboratory investigations of 
our patient.
diScUSSion
Multiple factors may have been involved in causing the patient’s 
hypogonadism; however, a detailed history and examination 
failed to suggest alternative reasons for it. Our patient presented 
at the age of 34 years which is quite unusual; however, Sumko et 
al7 described a similar case of a 27-year-old man who was found 
to have microphallus, undescended testes and scarce pubic hair, 
whereas Zhang et al8 reported a 34-year-old male with osteopo-
rosis, diabetes mellitus and metabolic syndrome. Both of these 
patients were discovered to have idiopathic HH while being 
evaluated for another disease. This hesitancy to seek medical 
care regarding delayed puberty may be because of the social 
stigma associated with sexual disorders; therefore, a lot of the 
cases might go unreported and present at a relatively advanced 
age. Our patient was 34 years old at presentation; therefore, 
the possibility of constitutionally delayed puberty was remote. 
However, at younger ages, it may be difficult to distinguish 
between constitutionally delayed puberty and HH. Two clinical 
features that might help to differentiate between the two are 
undescended testes and micropenis, which are more frequently 
found in HH.7
Failure of pulsatile GnRH secretion may be due to mutations 
in a number of genes such as PROK-2, FGFR1, etc. Further-
more, a protein, prokineticin-1, is involved in olfactory bulb 
development and release of GnRH. Mutations in this protein 
can also cause idiopathic HH which may be normosmic or 
anosmic (Kallmans syndrome).7 Although many genes have been 
linked with idiopathic hypogonadotropic hypogonadism (IHH), 
the majority of cases are due to genetic mutations which are yet 
unidentified.
Treatment of this disorder mainly depends on the desire for 
fertility. Androgen replacement alone can be used to reverse the 
problems associated with hypogonadism and is considerably less 
expensive than the other options available. Furthermore, our 
patient did not desire fertility at the time of presentation and 
considering the cost this was the best choice for him. However, 
pulsatile GnRH therapy and gonadotropins are better suited 
for patients who wish to become fertile because in addition to 
treating the low testosterone state they also stimulate spermato-
genesis.6
Previously, treatment was thought to be lifelong; however, 
Raivio et al2 described 15 patients who had sustained reversal 
of HH on discontinuation of therapy. Reversals occurred in 
five men treated with testosterone alone, three men treated 
with pulsatile GnRH therapy only and seven men who received 
a mixed regimen, including testosterone, gonadotropins or 
GnRH. Although the mechanism of reversal is unclear, the 
researchers speculated that because sex steroids were the only 
common medication given to all the patients with reversal, 
they somehow modify the hypothalamic neurons respon-
sible for producing GnRH. This might lead to reversal of 
HH and initiation of spermatogenesis. After the administra-
tion of testosterone, our patient’s HPG axis recovered with 
figure 1 MRI of the pituitary gland showing no pituitary 
pathology. HPR, half-plane representation; LP, left posterior; MRI axis: 
RA, right anterior.
table 1 Initial laboratory investigations of the patient
investigation value normal limit
Luteinising hormone (mlU/mL) 2.60 1.2–7.8
Follicular stimulating hormone (mlU/mL) 1.50 1.5–15.4
Testosterone (AM) (ng/dL) 55.99 249–836
Prolactin (ng/dL) 5.2 2–18
Thyroid-stimulating hormone (ulU/mL) 1.03 0.4–4.2
Free thyroxine (ng/dL) 1.13 0.89–1.76
table 2 Follow-up laboratory investigations of the patient
investigation value normal limit
Luteinising hormone (mlU/mL) 3.30 1.2–7.8
Testosterone (AM) (ng/dL) (on 
replacement)
643.3 249–836
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subsequent sexual maturation on clinical examination; there-
fore, he was advised to stop testosterone injections.
learning points
 ► Hypogonadism has significant psychosocial and health-
related effects which are easily treatable if this condition is 
caught early.
 ► Treatment depends on the desire for fertility and can be via 
testosterone replacement, pulsatile gonadotropin-releasing 
hormone therapy or gonadotropins.
 ► In a patient with hypogonadotropic hypogonadism being 
treated with testosterone, treatment should be temporarily 
discontinued after sexual maturation has occurred because a 
minority of cases may have achieved reversal.
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